Zacks: Brokerages Set $3.75 Target Price for SenesTech Inc (SNES)
Shares of SenesTech Inc (NASDAQ:SNES) have received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus price objective of $3.75 for the company and are anticipating that the company will post ($0.11) earnings per share for the current quarter, according to Zacks. Zacks has also assigned SenesTech an industry rank of 159 out of 255 based on the ratings given to related companies.
Several equities research analysts have recently weighed in on SNES shares. Zacks Investment Research lowered SenesTech from a “hold” rating to a “sell” rating in a research report on Friday, June 8th. ValuEngine raised SenesTech from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd.
SNES stock traded down $0.03 during mid-day trading on Tuesday, reaching $0.88. The company had a trading volume of 129 shares, compared to its average volume of 1,266,737. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.65 and a quick ratio of 4.89. The firm has a market capitalization of $18.43 million, a P/E ratio of -0.81 and a beta of 2.56. SenesTech has a fifty-two week low of $0.30 and a fifty-two week high of $3.87.
SenesTech (NASDAQ:SNES) last issued its earnings results on Monday, August 13th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.12). SenesTech had a negative return on equity of 205.29% and a negative net margin of 17,962.50%. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.40 million. analysts expect that SenesTech will post -0.5 EPS for the current year.
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Featured Story: What do I need to know about analyst ratings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.